Biopharmaceutical Company Demonstrates Positive Results In Lymphoma Treatment: $2.6M FDA Grant

Cutaneous T-cell lymphoma (CTCL) is a rare type of non-Hodgkin lymphoma that primarily affects the skin. While treatments exist, they are often limited in efficacy and scope, particularly in the early stages of the disease. The pursuit of more effective and safer treatments remains a high priority in the medical community. One promising development in this area is HyBryte™, a fluorescent light-activated synthetic hypericin therapy developed by Soligenix, Inc. (Nasdaq: SNGX). $Soligenix (SNGX.US)$